Review Article
Treatment for Recurrent Ovarian Cancer—At First Relapse
Table 5
Study result for platinum resistant recurrent ovarian cancer (combination).
| | GEM/weekly PTX | GEM/PLD | PLD/Topotecan |
| Dose (mg/) | 1000/80 | 1000/30 | 30/1 | | day 1.8. 15/4w | day 1.8/day l/3w | day l/day l–5/3w |
| Author | Garcia et al. [12] | Ferrandina et al. [19] | Verhaar-Langereis et al. [20] | | | | | Number of patients | 35 | 66 | 27 | | | | | Response rate | | | | CR PR (%) | 40 | 21.6 | 28 | | | | | SD (%) | 77 | 53.9 | 72 | | | | | PFS (months) | 5.7 | 20 weeks | 30 weeks | | | | | OS (months) | 13.1 | 50 weeks | 41 weeks |
|
|